Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A
5(100.0%)
5Total
N/A(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06300125Recruiting

Percutaneous Cryoablation of Low-risk Early Breast Cancer

Role: collaborator

NCT02399124Not ApplicableActive Not Recruiting

Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma

Role: lead

NCT02200705Not ApplicableCompleted

Cryoablation of Low Risk Small Breast Cancer- ICE3 Trial

Role: lead

NCT00910312Not ApplicableCompleted

ICE-SENSE™ Cryotherapy for Breast Fibroadenoma Trial

Role: lead

NCT01735812Not ApplicableWithdrawn

Laparoscopic Cryoablation of Uterine Fibroids

Role: lead

NCT01671943Not ApplicableCompleted

Cryotherapy for Breast Cancer Trial

Role: lead

All 6 trials loaded